BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 15, 2005
View Archived Issues
THP's Transgenic Rabbits To Make Polyclonal Drugs
Read More
BioVeris Licenses Exclusive Vaccine Rights From Baxter
Read More
U.S. Patent Disclosures
Read More
Other News To Note
Read More
Alexion Raises $67M As Lead Drugs Near End Of Phase III
Just days after Alexion Pharmaceuticals Inc. said it completed enrollment in a pivotal trial of its cardiovascular drug, pexelizumab, ahead of schedule, the company priced a public offering to raise $66.9 million. (BioWorld Today)
Read More
$33M Financing, Loans Could Take Xenogen To Profitability
Read More
